



# **Wholesale Prescription Drug Importation Program Report**

---

**As Required by House Bill 25,  
88<sup>th</sup> Legislature, Regular Session, 2023**

**Texas Health and Human Services  
December 1, 2025**



**TEXAS**  
Health and Human  
Services

# Table of Contents

**Executive Summary .....3**

## Executive Summary

The Wholesale Prescription Drug Importation Program Report for fiscal year 2025 is submitted in accordance with Health and Safety Code Section 444.007, as added by House Bill (H.B.) 25, 88th Legislature, Regular Session, 2023, requiring the Health and Human Services Commission (HHSC) to submit an annual report to the Governor and the Legislature regarding the operation of the program during the preceding state fiscal year.

H.B. 25, the Wholesale Prescription Drug Importation Act, requires HHSC to establish a wholesale prescription drug importation program to provide lower cost prescription drugs available outside the United States to Texas consumers at a lower cost.

Due to a need for appropriations to begin program operations, there are no new implementation activities to report during fiscal year 2025. The recommendation sections of the previous reports provide alternative opportunities for implementation, including the potential transfer of the Wholesale Prescription Drug Importation program under the authority of the Texas Pharmaceutical Initiative (TPI) Board as established by House Bill (H.B.) 4990, 88th Legislature, Regular Session, 2023. HHSC remains committed to acting upon future direction of the legislature on this program.